Epilepsy advocates push for public coverage of costly new drug Xcopri in Canada.

Epilepsy patients and advocates are pushing for public coverage of Xcopri, a new anti-seizure drug approved in Canada in 2023. The medication, also known as cenobamate, has shown promising results in reducing seizures and improving patients' quality of life. Despite its benefits, Xcopri is not covered under provincial drug plans in Saskatchewan and Ontario, leaving patients to pay up to $3,200 annually. Advocates argue that the drug offers better efficacy compared to other medications and hope provincial governments will reconsider coverage.

November 27, 2024
15 Articles